Price movement over the last 24 hours
Agilent Technologies Inc vs McDonald's Corp — how do they compare? Agilent Technologies Inc trades at $128.84 (market cap $37.04B), while McDonald's Corp trades at $277.09 (market cap $200.51B). The key difference: McDonald's Corp is far larger — about 5.4× Agilent Technologies Inc's market cap, and McDonald's Corp pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| A | MCD | |
|---|---|---|
Market Cap | $37.04B | $200.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $341.06 |
52-Week Low | $110.24 | $264.54 |
Enterprise Value | $38.59B | $254.22B |
Dividend Yield | 0.78% | 2.64% |
Volume | — | 2,230,036 |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
McDonald's (MCD) trades at $279.5, down 0.4% on the day, as the stock navigates a challenging consumer environment. The company reported solid Q1 2026 earnings that beat expectations, with revenue reaching $26.89B in 2025 and a robust net income margin of 31.62%. Technical analysis shows a bullish overall signal despite mixed moving averages, with key support at $275 and resistance at $282. Recent news highlights the company's new 'McDonald's>NEXT' growth strategy focused on automation and menu innovation to win back customers.
The outlook for MCD is cautiously optimistic, supported by strong analyst consensus (58% Buy rating) and a $325.50 price target implying significant upside. Investment opportunities include the company's durable franchise model, consistent dividend payments, and strategic initiatives to improve operations. Key risks involve persistent inflationary pressures on franchisee margins, intense competition in the value segment, and execution challenges of the new growth strategy amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →